Florida / New York / No Carolina
Ph: 561.316.3330

Julie Sawyer Montgomery | Appointed Executive Vice President for Diagnostics at Danaher Corporation

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • She holds a Bachelor of Arts in Economics from Columbia University, a Master of Music from the Eastman School of Music, and a Master of Business Administration from Harvard Business School.

Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.

Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher’s Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.

Rainer Blair commented: “Julie’s exceptional leadership has been instrumental in driving growth and improving performance at Beckman Coulter Diagnostics and, more recently, across our Clinical Diagnostics businesses. During her tenure Julie has shown tremendous commitment to supporting our customers, building winning teams, driving innovation and leading with the Danaher Business System. I look forward to seeing Julie apply her skills and experiences to help ensure the ongoing success of our entire Diagnostics franchise, as we work to improve outcomes for patients with faster, more accurate diagnoses.”

Ms. Sawyer Montgomery joined Danaher in 2017. In her current role, she is responsible for providing strategic leadership across Danaher’s Diagnostics businesses. Previously, she held positions of increasing responsibility and was the President of Beckman Coulter Diagnostics. Before joining Danaher, Ms. Sawyer Montgomery held leadership roles at Hospira Infusion Systems, Boston Scientific and Boston Consulting Group. She holds a Bachelor of Arts in Economics from Columbia University, a Master of Music from the Eastman School of Music, and a Master of Business Administration from Harvard Business School.

Mr. Weidemanis joined Danaher in 2011. Among his many accomplishments, he most recently led our Diagnostics businesses and previously oversaw our Product Identification and Water Quality platforms, which are now part of Veralto Corporation.

Mr. Blair added: “It has been a privilege to work alongside Joakim for the past 13 years. His contributions have been pivotal in evolving strategy, furthering growth, innovation, operational excellence and developing leaders across our businesses. On behalf of our Board of Directors, associates and shareholders, I want to thank Joakim for helping to make Danaher a better, stronger company.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

LIfT BioSciences Appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors

Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of LIfT’s Board of Directors, I am pleased to welcome Tony to the Company as Chairman. Tony has extremely relevant experience, having played a key role in successfully bringing three new drug modalities to the market, extensive experience in immuno-oncology, and has helped build several multi-billion-dollar companies from start-up stage. This wealth of experience will prove invaluable to LIfT as we prepare to move into clinical trials for our allogeneic first-in-class neutrophil-based immuno-cell therapy and other exciting pipeline developments.”

Ronil Patel Appointed Chief Business Officer at RevOpsis Therapeutics

Ronil Patel currently serves as a strategic advisor to Collage Venture Partners and was previously the Chief Business Officer at Ocuphire Pharma, a publicly traded ophthalmology biotechnology company. Prior to Ocuphire, Patel led business development for Point Guard Partners and Oculos Clinical Research (now iuvo Bioscience). Patel has been instrumental in biotech research and development and global business expansion. He has also contributed to teams that have secured approximately $100 million in funding and finalized licensing and exit deals valued at over $500 million.

Mark Eisner MD, M.P.H. Appointed Chief Medical Officer at Vir Biotechnology

Mark Eisner MD comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In this role, he led all development functions which included biometrics, regulatory, clinical science, clinical operations, drug safety, and pharmacology.

By using this website you agree to accept Medical Device News Magazine Privacy Policy